190 related articles for article (PubMed ID: 18540932)
21. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels.
Schmid HP; Ravery V; Billebaud T; Toublanc M; Boccon-Gibod LA; Hermieu JF; Delmas V; Boccon-Gibod L
Urology; 1996 May; 47(5):699-703. PubMed ID: 8650868
[TBL] [Abstract][Full Text] [Related]
22. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis.
Weight CJ; Kim SP; Jacobson DJ; McGree ME; Boorjian SA; Thompson RH; Leibovich BC; Karnes RJ; St Sauver J
Eur Urol; 2013 Jun; 63(6):1021-7. PubMed ID: 23313032
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
Mochtar CA; Kiemeney LA; van Riemsdijk MM; Barnett GS; Laguna MP; Debruyne FM; de la Rosette JJ
Eur Urol; 2003 Dec; 44(6):695-700. PubMed ID: 14644122
[TBL] [Abstract][Full Text] [Related]
24. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.
Shim HB; Lee JK; Jung TY; Ku JH
Prostate Cancer Prostatic Dis; 2007; 10(2):143-8. PubMed ID: 17199133
[TBL] [Abstract][Full Text] [Related]
25. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
26. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; deKernion JB; Walsh PC; Scardino PT; Lange PH; Subong EN; Parson RE; Gasior GH; Loveland KG; Southwick PC
JAMA; 1998 May; 279(19):1542-7. PubMed ID: 9605898
[TBL] [Abstract][Full Text] [Related]
27. Prostate hyperplasia in St Mary's Hospital Lacor: utility of prostate specific antigen in screening for prostate malignancy.
Okidi R; Opira C; Sambo VDC; Achola C; Ogwang DM
Afr Health Sci; 2020 Sep; 20(3):1259-1263. PubMed ID: 33402973
[TBL] [Abstract][Full Text] [Related]
28. Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older.
Berges R; Oelke M
World J Urol; 2011 Apr; 29(2):171-8. PubMed ID: 21221974
[TBL] [Abstract][Full Text] [Related]
29. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
31. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment.
Liao CH; Chung SD; Kuo HC
Urology; 2011 Dec; 78(6):1373-8. PubMed ID: 21962879
[TBL] [Abstract][Full Text] [Related]
32. High grade intraepithelial neoplasia of prostate is associated with values of prostate specific antigen related parameters intermediate between prostate cancer and normal levels.
Obralic N; Kulovac B
Bosn J Basic Med Sci; 2011 Nov; 11(4):223-7. PubMed ID: 22117828
[TBL] [Abstract][Full Text] [Related]
33. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
34. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
[TBL] [Abstract][Full Text] [Related]
35. Detection of prostate cancer in males with prostatism.
Lepor H; Owens RS; Rogenes V; Kuhn E
Prostate; 1994 Sep; 25(3):132-40. PubMed ID: 7520577
[TBL] [Abstract][Full Text] [Related]
36. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Sutcliffe S; Grubb Iii RL; Platz EA; Ragard LR; Riley TL; Kazin SS; Hayes RB; Hsing AW; Andriole GL;
BJU Int; 2012 Oct; 110(7):1050-9. PubMed ID: 22429766
[TBL] [Abstract][Full Text] [Related]
37. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms.
Vesely S; Knutson T; Damber JE; Dicuio M; Dahlstrand C
Scand J Urol Nephrol; 2003; 37(4):322-8. PubMed ID: 12944191
[TBL] [Abstract][Full Text] [Related]
38. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
39. High serum prostate-specific antigen levels in the absence of prostate cancer in Middle-Eastern men: the clinician's dilemma.
Kehinde EO; Sheikh M; Mojimoniyi OA; Francis I; Anim JT; Nkansa-Dwamena D; Al-Awadi KA
BJU Int; 2003 May; 91(7):618-22. PubMed ID: 12699471
[TBL] [Abstract][Full Text] [Related]
40. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.
Moore AL; Dimitropoulou P; Lane A; Powell PH; Greenberg DC; Brown CH; Donovan JL; Hamdy FC; Martin RM; Neal DE
BJU Int; 2009 Dec; 104(11):1592-8. PubMed ID: 19549125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
